Takeda Pharmaceutical Company Limited
Osaka, Japan, And São Jerônimo, Brazil (ots/PRNewswire) - ? Takeda Pharmaceutical Company Limited (Osaka, Japan, "Takeda") and Multilab Industria e Comercio de Produtos Farmaceuticos Ltda. (Rio Grande do Sul, Brazil, "Multilab") today jointly announced that both parties have signed an agreement whereby Takeda Farmaceutica Brasil Ltda. (Sao Paulo, Brazil, "Takeda ...
http://resources.euroadhoc.com/us/6PEp8eVI issuer: LifeWatch AG Rundbuckstrasse 6 CH-8212 Neuhausen am Rheinfall phone: +41 52 632 00 50 FAX: +41 52 632 00 51 mail: users@lifewatch.com WWW: www.lifewatch.com sector: Healthcare Providers ISIN: ...
http://resources.euroadhoc.com/us/ex4YiVpG issuer: LifeWatch AG Rundbuckstrasse 6 CH-8212 Neuhausen am Rheinfall phone: +41 52 632 00 50 FAX: +41 52 632 00 51 mail: users@lifewatch.com WWW: www.lifewatch.com sector: Healthcare Providers ISIN: CH0012815459 indexes: SPI, SPIEX stockmarkets: free trade: Berlin, Open Market / XETRA: Frankfurt, Main Standard: SIX Swiss ...
Hatfield, England (ots/PRNewswire) - ? Reimbursement granted for Zebinix(R) (eslicarbazepine acetate) as adjunctive therapy for adults with partial-onset seizures Eisai Europe Limited today announces the launch of Zebinix(R) (eslicarbazepine acetate) which will receive full reimbursement from the Swedish health authorities. Once-daily Zebinix is indicated as an adjunctive (add-on) therapy for adults with partial-onset ...
Shire Pharmaceuticals Group Plc
Nyon, Switzerland (ots/PRNewswire) - Significantly lower proportion of subjects experiencing treatment failure whilst receiving LDX in the randomised withdrawal period, compared to those subjects receiving placebo.[1] Today, at the EUNETHYDIS 2nd International ADHD Conference, Shire AG , the global specialty ...
Hatfield, England (ots/PRNewswire) - Eisai announced today that 12 abstracts highlighting new study results will be presented during the 48th Annual Meeting of the American Society of Clinical Oncology (ASCO), taking place in Chicago, USA, from 1-5 June 2012. These studies highlight Eisai's current product portfolio and oncology pipeline, reinforcing the company's ...
ArQule, Inc. and Daiichi Sankyo, Co., Ltd.
Woburn, Massachusetts And Tokyo (ots/PRNewswire) - ArQule, Inc. and Daiichi Sankyo, Co., Ltd. (TSE 4568) today announced that an oral presentation at the Annual Meeting of the American Society of Clinical Oncology (ASCO) will feature Phase 2 trial data with tivantinib as a single agent investigational second-line ...
London (ots/PRNewswire) - The European Alliance for Access to Safe Medicines (EAASM) is calling for authorities to act now to clarify the conditions under which medicines can be used outside of their approved status. For example, the recent report from the US-based "CATT" study shows an increased risk of serious adverse events with the unlicensed (but widely-used) drug ...
Munich (ots/PRNewswire) - **Not be used by UK media** To mark this year's World Hypertension Day, Daiichi Sankyo Europe has announced a website for patients offering more information about hypertension management and treatment. http://www.hypertensioncare.eu is now available to patients and physicians across Europe ...
Sunnyvale, California (ots/PRNewswire) - Conference Presentations Highlighted Benefits of the CyberKnife(R) System's Motion Management and the TomoTherapy(R) System's Daily Image-Guidance Accuray Incorporated , the premier radiation oncology company, announced today that for the first time in Europe, at ESTRO 31 ...
Bristol-Myers Squibb GmbH & Co. KGaA
Paris (ots/PRNewswire) - - Results of head-to-head study comparing two biologic drugs on a background of methotrexate for the treatment of moderate to severe rheumatoid arthritis to be presented Bristol-Myers Squibb Company [http://www.bms.com ] today announced that the company will present 18 abstracts on abatacept ...
Istanbul, Turkey (ots/PRNewswire) - Turkcell , the leading communications and technology company in Turkey, has united all of its services and projects aimed at facilitating the lives of disabled citizens' and their participation in daily life under the "People Without Boundaries" roof in line with its vision of using technology to provide equal opportunities to all segments of society. Turkcell's services without ...
London (ots/PRNewswire) - http://www.fi-sportsnutrition.com Traditionally, sports nutrition products have been focused towards elite level athletes but the market is being transformed by the emergence of regular consumers who are not always interested in sports yet recognise the role that nutrition can play in helping their general health and wellness. With the active ...
http://resources.euroadhoc.com/us/xB7woU7B http://resources.euroadhoc.com/us/3qJFtaGQ issuer: LifeWatch AG Rundbuckstrasse 6 CH-8212 Neuhausen am Rheinfall phone: +41 52 632 00 50 FAX: +41 52 632 00 51 mail: users@lifewatch.com WWW: www.lifewatch.com sector: Healthcare Providers ISIN: CH0012815459 ...
http://resources.euroadhoc.com/us/LZrurKZz issuer: LifeWatch AG Rundbuckstrasse 6 CH-8212 Neuhausen am Rheinfall phone: +41 52 632 00 50 FAX: +41 52 632 00 51 mail: users@lifewatch.com WWW: www.lifewatch.com sector: Healthcare Providers ISIN: ...
issuer: LifeWatch AG Rundbuckstrasse 6 CH-8212 Neuhausen am Rheinfall phone: +41 52 632 00 50 FAX: +41 52 632 00 51 mail: users@lifewatch.com WWW: www.lifewatch.com sector: Healthcare Providers ISIN: CH0012815459 indexes: SPI, SPIEX stockmarkets: free trade: Berlin, Open Market / XETRA: Frankfurt, Main Standard: SIX Swiss Exchange language: English ...
London (ots/PRNewswire) - EvaluatePharma Ltd, a leading source for life science sector analysis and the first to supply reliable consensus forecasts of global drug sales, revealed today that Novartis is expected to take the top spot amongst the world's pharmaceuticals manufacturers, in terms of prescription (Rx) drug sales, starting in 2014 and remains at the top ...
Shire Pharmaceuticals Group Plc
Philadelphia (ots/PRNewswire) - - Company Plans to Conduct Additional Analyses of These Preliminary Data Shire plc [http://www.shire.com/shireplc/en/home ] , the global specialty biopharmaceutical company, today announced positive top-line results from a Phase 2 study to evaluate the safety and efficacy of ...
http://resources.euroadhoc.com/us/uwOkosUu issuer: LifeWatch AG Rundbuckstrasse 6 CH-8212 Neuhausen am Rheinfall phone: +41 52 632 00 50 FAX: +41 52 632 00 51 mail: users@lifewatch.com WWW: www.lifewatch.com sector: Healthcare Providers ISIN: CH0012815459 indexes: SPI, SPIEX stockmarkets: free trade: ...
Calgary, Alberta (ots/PRNewswire) - This Novel Epigenetic Mechanism Defines an Entirely New Class of Therapeutic TSX Exchange Symbol: RVX Resverlogix Corp. ("Resverlogix" or the "Company") today announces the "Mechanism of Action" (MoA) by which RVX-208 increases apolipoprotein A-I (ApoA-I) production. Our data shows RVX-208 to be an inhibitor of the Bromodomain and ...
Frankfurt And Hatfield, England (ots/PRNewswire) - ? The German Federal Joint Committee (G-BA), the supreme decision-making body of the self-governing medical system in Germany, announced that it considers the use of Halaven(R) (eribulin) to have additional benefit versus comparative treatments, defined by the G-BA ...
http://resources.euroadhoc.com/us/lBLJuRAt issuer: LifeWatch AG Rundbuckstrasse 6 CH-8212 Neuhausen am Rheinfall phone: +41 52 632 00 50 FAX: +41 52 632 00 51 mail: users@lifewatch.com WWW: www.lifewatch.com sector: Healthcare Providers ISIN: ...
Calgary, Alberta (ots/PRNewswire) - Dr. Stephen J. Nicholls joins as guest speaker TSX Exchange Symbol: RVX Resverlogix Corp. ("Resverlogix" or the "Company") is pleased to announce for the first time the "Mechanism of Action" (MoA) by which RVX-208 increases apolipoprotein A-I (ApoA-I) production. Please join us via Conference Call & Webcast on Monday, April 23, 2012, ...
Barcelona, Spain (ots/PRNewswire) - - Retrospective sub-analyses from ADVANCE, ILLUMINATE and REALIZE Phase 3 studies will be presented at European Association for the Study of the Liver (EASL) 2012 - Janssen Pharmaceutica NV (Janssen) will present new data for INCIVO (telaprevir) from Phase 3 retrospective ...
Hatfield, England (ots/PRNewswire) - Reimbursement granted for Zebinix(R) as adjunctive therapy for adults with partial-onset seizures Eisai Europe Limited announces the launch of Zebinix(R) (eslicarbazepine acetate) in France. Upon launch, this novel epilepsy drug will receive full reimbursements from the French health authorities. Once-daily eslicarbazepine acetate is indicated as an adjunctive (add-on) therapy for ...
Hatfield, England (ots/PRNewswire) - New EMEA Dubai Office Part of Expansion Plans into Middle East and Parts of Africa PRESS RELEASE NOT INTENDED FOR DUBAI MEDIA Japanese company Eisai is expanding its geographical and patient reach by opening a new regional representative office in Dubai today. The Eisai EMEA (Europe, Middle East and Africa) Dubai branch office, located in Dubai Healthcare City (DHCC), marks the ...
Monheim, Germany (ots/PRNewswire) - Four WebConferences from 7th International CVBD World Forum attract more than 3,000 viewers from around the world to hear case studies from leading international experts Bayer Animal Health today announced that the recent educational WebConfererences following the Seventh Canine Vector-Borne Disease (CVBD) World Forum were watched by ...
Hatfield, England (ots/PRNewswire) - Child-friendly formulation now available for the treatment of Lennox-Gastaut syndrome Eisai Europe Limited today announced the launch of Inovelon(R) (rufinamide) oral suspension in Denmark for adjunctive (add-on) treatment of seizures associated with Lennox-Gastaut syndrome (LGS), in children four years and older. Many patients who receive the orphan drug rufinamide are children, ...
Shire Pharmaceuticals Group Plc
Dublin (ots/PRNewswire) - Shire plc , the global specialty biopharmaceutical company, will announce first quarter 2012 earnings on Thursday April 26, 2012. Results press release will be issued at: 12:00 BST / 07:00 EDT Investor conference call time: 14:00 BST / 09:00 EDT Live conference call for investors: Angus Russell, Chief Executive Officer and Graham Hetherington, ...
Shire Pharmaceuticals Group Plc
Dublin (ots/PRNewswire) - Shire plc , the global specialty biopharmaceutical company, today announced that it has signed an agreement to acquire substantially all the assets of Pervasis Therapeutics. Shire will provide Pervasis with an upfront payment, plus potential post-closing milestone payments that are dependent on Shire's achievement of certain clinical ...